Stockreport

Denali Therapeutics Announces Data Presentations on Enzyme TransportVehicle™ Programs for Hunter Syndrome, Sanfilippo Syndrome Type A and Pompe Disease at Upcoming 2026 WORLDSymposium™

Denali Therapeutics Inc.  (DNLI) 
Last denali therapeutics inc. earnings: 8/6 04:30 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.denalitherapeutics.com
PDF Hunter syndrome (MPS II) presentations will include analysis from continued follow-up of Phase 1/2 data for tividenofusp alfa (DNL310), currently under FDA Priority Revi [Read more]